GGrantIndex
← Search

Roswell Park Cancer Institute Center Support Grant

$91,296P30FY2006CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

DESCRIPTION (provided by applicant): Roswell Park Cancer Institute (RPCI) requests renewal of its National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) for years 27-31. This application reflects significant changes in leadership, faculty, programmatic and scientific direction, facilities and governance over the past few years. RPCI has, under the leadership of David C. Hohn, MD, President and CEO, recruited new senior leaders for basic, clinical, translational and population science. The CCSG scientific enterprise has been consolidated into five programs and 14 shared resources. These CCSG Programs now include Therapeutics, Biophysical Therapies, Tumor Immunology, Genetics and Cancer Prevention; four of these programs are under new leadership. The Institute has increased its scientific capabilities through the recruitment of 43 new members to CCSG Programs in both the laboratory and clinical research areas. With these recruitments and existing strength, peer-reviewed grant funding has significantly increased in the past year. RPCI and programmatic strategic planning has generated an overall Institute strategy for growth and direction with programmatic strategies targeted toward scientific excellence and multidisciplinary approaches. The overall vision of RPCI over the next five years will focus on the identification, validation and exploitation of targets for cancer treatment and control based on substantial inter-programmatic efforts from all of the Programs. To accommodate the growth of the CCSG membership, development of a new 170,000 gross square feet basic research laboratory building is underway and will be finished by 2005. We are requesting $3.0 million which will support five scientific programs, 14 shared resources, leadership, developmental funds, planning and evaluation and administration. Recruitment, reorganization and institutional commitment have reinvigorated RPCI as a comprehensive cancer center with focused vision for the future and for the development of excellence in all aspects of cancer research.

View original record on NIH RePORTER →